PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer (NCT01737619)
Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan, which are taken at the same time from the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. Lymph node mapping uses a radioactive dye, called indocyanine green solution, to identify lymph nodes that may contain cancer cells. PET/CT and sentinel lymph node mapping may be better ways than surgery to identify cancer in the lymph nodes.
Who can join: Review the eligibility criteria below.
Location: Lyndon Baines Johnson General Hospital — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Lyndon Baines Johnson General Hospital — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
- The Woman's Hospital of Texas — Houston, Texas
- MD Anderson Regional Care Center-Katy — Houston, Texas
- MD Anderson Regional Care Center-Bay Area — Nassau Bay, Texas
- MD Anderson Regional Care Center-Sugar Land — Sugar Land, Texas
- MD Anderson Regional Care Center-The Woodlands — The Woodlands, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Clear Cell Adenocarcinoma
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer — Birmingham, Alabama
- Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers — Houston, Texas
- Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer — Palo Alto, California
Explore by condition: All Endometrial Clear Cell Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.